Page 15 - Pharmaceutical M5 Biopharma


Sponsored Feature  15

Bioanalysis Accelerating the pre-clinical/clinical phase

nSMOL™ Antibody BA Kit Antibody Trypsin- Remove All
Collection immobilized Particles
Simplifying workflows and enhancing sensitivity wash Nanoparticles
Added

Plasma + Protein A Beads (~50 μm with 100 nm pores) +
Protein A Beads Trypsin Nanoparticles (200 nm diameter)

All antibodies are trapped in pores of Nanoparticles cannot enter the pores but Fab-selective proteolysis releases
Protein A beads trypsin can partially access the antibodies CDR peptides

nSMOL + LCMS LBA Development of LCMS bioanalysis in
Ab for collection/detection Not needed 6++ months to develop combination with nSMOL proteolysis is
Cross reactivity test Not needed Mandatory and tricky much faster, and can dramatically accelerate
Pre-validation 1-3 days 2-3 weeks the total R&D period of biologics by
Full validation 3-4 w 3-4 w alleviating the bottlenecks that typically
occur when entering the preclinical and
Sample prep 3-5 h 2-4 h clinical phase.
Data features Highly selective and reliable, Highly dependent on quality of
wide dynamic range, easy to detection Ab.
multiplex, independent of
antibodies

www.shimadzu.com